FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Benzinga.com16d
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
Also Read: Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal This approval, granted following FDA Priority Review, is supported ...
Why Johnson & Johnson’s CEO Welcomes Scrutiny
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
Is Johnson & Johnson Stock a Buy?
The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Medical News Today10d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...